Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JATT JATT Acquisition	$1.66 -3.5%	$1.36	$7.80 ▼ $12.38	$28.64M	N/A	41,322 shs	471,199 shs
OKYO OKYO Pharma	$2.65 +0.4%	$2.70	$0.85 ▼ $3.35	$99.67M	-0.09	149,165 shs	710,371 shs
SKYE Skye Bioscience	$3.51 +7.3%	$3.55	$1.14 ▼ $7.47	$108.77M	2.21	349,716 shs	394,378 shs
ZURA Zura Bio	$1.66 -3.5%	$1.37	$0.97 ▼ $5.07	$113.50M	-0.06	531,321 shs	470,899 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JATT JATT Acquisition	-3.49%	+16.90%	+27.69%	+49.55%	-49.54%
OKYO OKYO Pharma	0.00%	-18.96%	-8.62%	+79.05%	+165.03%
SKYE Skye Bioscience	0.00%	-0.28%	-5.65%	+87.20%	-22.00%
ZURA Zura Bio	0.00%	+16.90%	-15.31%	+49.55%	-48.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	3.1384 of 5 stars	3.5	5.0	0.0	0.0	3.1	1.7	0.0
SKYE Skye Bioscience	1.9151 of 5 stars	3.6	2.0	0.0	0.0	3.2	0.0	0.0
ZURA Zura Bio	3.5333 of 5 stars	3.6	5.0	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JATT JATT Acquisition	0.00	N/A	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	164.15% Upside
SKYE Skye Bioscience	3.14	Buy	$15.50	341.60% Upside
ZURA Zura Bio	3.13	Buy	$14.17	753.41% Upside

Current Analyst Ratings Breakdown

Latest JATT, SKYE, ZURA, and OKYO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/14/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JATT JATT Acquisition	N/A	N/A	$0.06 per share	27.08	($0.53) per share	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$1.41 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	N/A	-76.03%	-69.20%	N/A
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-47.44%	-38.81%	N/A

Latest JATT, SKYE, ZURA, and OKYO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JATT JATT Acquisition	N/A	0.15	0.15
OKYO OKYO Pharma	N/A	0.40	0.40
SKYE Skye Bioscience	N/A	6.09	11.85
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JATT JATT Acquisition	47.97%
OKYO OKYO Pharma	2.97%
SKYE Skye Bioscience	21.09%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
JATT JATT Acquisition	20.00%
OKYO OKYO Pharma	40.46%
SKYE Skye Bioscience	4.50%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable
SKYE Skye Bioscience	11	30.99 million	29.59 million	Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

JATT, SKYE, ZURA, and OKYO Headlines

Recent News About These Companies

Zura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at Oppenheimer

August 17 at 10:47 AM | marketbeat.com

Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

August 17 at 8:29 AM | marketbeat.com

Zura Bio's (ZURA) Buy Rating Reiterated at Chardan Capital

August 17 at 2:59 AM | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 16 at 12:29 PM | marketbeat.com

Zura Bio price target lowered to $16 from $17 at Oppenheimer

August 15 at 8:33 PM | msn.com

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14 at 8:15 AM | businesswire.com

Zura Bio (ZURA) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT, SKYE, ZURA, and OKYO Company Descriptions

JATT Acquisition NYSE:JATT

$1.66 -0.06 (-3.49%)

As of 08/15/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

OKYO Pharma NASDAQ:OKYO

$2.65 +0.01 (+0.38%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.64 -0.01 (-0.23%)

As of 08/15/2025 07:59 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Skye Bioscience NASDAQ:SKYE

$3.51 +0.24 (+7.34%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.50 0.00 (-0.14%)

As of 08/15/2025 07:56 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Zura Bio NASDAQ:ZURA

$1.66 -0.06 (-3.49%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.06 (+3.86%)

As of 08/15/2025 07:53 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time